Old drug works new tricks for iron overload heart disease

September 15, 2003

Researchers at the University of Toronto and Toronto General Hospital have made a discovery that could prevent damage to the heart, pancreas and pituitary gland from excess iron with a simple pill. This could save many lives around the world and spare patients from the cumbersome treatments currently available.

The scientists have found that oral medications currently used to treat hypertension are also effective at blocking excessive iron from entering certain critical organs and causing permanent damage. Their new research is published in the Sept. 15 issue of Nature Medicine.

"Hereditary hemochromatosis and secondary iron overload due to illnesses such thalassemia and sickle cell anemia are genetic disorders associated with elevated iron levels that particularly affect people of North American, European, Mediterranean or Asian descent," says Dr. Peter Backx, professor of physiology and medicine at U of T in the Heart & Stroke/Richard Lewar Centre of Excellence and senior author of the paper. "What was never understood was why individuals with this genetic disorder are very susceptible to developing heart disease and dysfunction of the pancreas and pituitary gland. Why were these tissues so sensitive to elevated iron levels? We found that for these people, the same calcium channels that are critical for functioning in these organs by transporting calcium into the cells are also the culprits responsible for transporting iron and ultimately causing the damage."

L-type calcium channels are part of the body's natural functioning, explains Dr. Gavin Oudit, a PhD student in the clinician investigator program at U of T, a cardiology resident at Toronto General Hospital, University Health Network, and lead author of the paper. In the case of the heart, these channels allow calcium into the heart and cause it to contract. "For people with genetic disorders who have excess iron in their blood, however, the unfortunate byproduct of these calcium channels is that they also allow iron into the heart cells. In iron overload disorders, a large percentage of those patients end up dying of cardiomyopathy (disease of the heart), which is now reaching epidemic levels worldwide."

Oral medications like calcium channel blockers amlodipine, verapamil and diltiazem were tested on mice with iron overload cardiomyopathy. "This surprisingly simple and effective strategy may potentially open an entirely new door to treatment for patients worldwide suffering from iron overload. This is particularly important for patients in many countries who currently could not afford any treatment at all for this deadly condition because of the cost," says Dr. Peter Liu, director of the Heart & Stroke/Richard Lewar Centre of Excellence and professor of medicine and physiology at U of T, cardiologist at Toronto General Hospital and a senior investigator of the study.

However, Liu cautions that before rushing to this new treatment, scientists and physicians still need to do careful and systematic testing on a larger patient sample to understand who benefits the most from calcium channel blockers and how much to use. "Since the drugs being considered have already been approved for human use, the potential for clinical benefit could be realized much earlier than other treatment strategies."

The current method of treating iron overload in the heart is chelation therapy, a difficult and cumbersome process involving infusions of a solution containing compounds that bind to the iron, which can then excrete the iron from the body. However, the researchers say this method is playing catch up, not a preventative method in dealing with iron overload.

"For patients with iron overload right now, the choices are either nightly needles under the skin for hours on end to remove the iron or face certain death from heart failure. The drugs currently used are also extremely expensive, so many patients around the world die at a young age from heart failure" says Liu.

According to the researchers, iron-related disorders are a modern disease. In the case of genetic blood disorders, iron overload results directly from regular transfusions that the patients receive in order to sustain life. In other cases, a common genetic defect in the control of iron intake into the body leads to excessive iron deposits into critical organs such as the heart. Our overall exposure to iron has increased through changes in diet and nutrition, they say. With grains and cereals now fortified with iron, and people consuming much more meat than in the past, these many sources of iron are causing damage to those who are genetically unable to adequately metabolize and excrete it.

Other researchers on this paper are Hui Sun, Maria Trivieri, Fayez Dawood and Mehrdad Yazdanpanah of the Heart & Stroke/Richard Lewar Centre of Excellence and the Departments of Medicine and Physiology at U of T; Cameron Ackerley and Greg Wilson of pathology at The Hospital for Sick Children; and Sheryl Koch and Arnold Schwartz of the Institute of Molecular Pharmacology and Biophysics at the University of Cincinnati Medical Center.

Support for this research was provided by Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario and National Institutes of Health.
-end-
CONTACT:


Janet Wong
U of T Public Affairs
416-978-5949
jf.wong@utoronto.ca

Peter Backx
Department of Physiology
416-946-8112
p.backx@utoronto.ca

Gavin Oudit
Department of Physiology
416-946-8110
gavin.oudit@utoronto.ca

Peter Liu
Heart & Stroke/Richard Lewar Centre of Excellence
416-340-3035
peter.liu@utoronto.ca

University of Toronto

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.